Item 2.02. Results of Operations and Financial Condition.
Oncternal Therapeutics, Inc. ("Oncternal") estimates that its cash and cash
equivalents were approximately $90.8 million as of December 31, 2021. This
amount is unaudited and preliminary and is subject to completion of financial
closing procedures. As a result, this amount may differ materially from the
amount that will be reflected in Oncternal's financial statements as of and for
the quarter ended December 31, 2021.
The information in this Item 2.02 shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, except as shall be expressly set forth by specific reference in such
a filing.
Forward-Looking Statements
Oncternal cautions readers that statements contained in this report regarding
matters that are not historical facts are forward-looking statements. These
statements are based on Oncternal's current beliefs and expectations. Such
forward-looking statements include Oncternal's estimated cash and cash
equivalents as of December 31, 2021. Such forward-looking statements involve
risks and uncertainties that could cause actual results to differ materially
from predicted or expected results. Such risks and uncertainties include, but
are not limited to, potential changes in estimated cash and cash equivalents
based on the completion of financial closing procedures and release of complete
fourth quarter 2021 results, and other risks described in Oncternal's filings
with the Securities and Exchange Commission. Oncternal cautions readers not to
place undue reliance on these forward-looking statements, which speak only as of
the date hereof, and Oncternal undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their entirety by
this cautionary statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
1
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses